Two cases of disseminated tuberculosis after negative screening before adalimumab treatment for immune-mediated inflammatory diseases
Rita Fernanda Cortez de Almeida, Ricardo Cortez Cardoso Penha, Lívia do Nascimento Barbosa
JAAD Case Reports · 2019-11
Abstract
Adalimumab (Humira) is a fully human, monoclonal antibody against tumor necrosis factor (TNF)-α.1 It is indicated for several immune-mediated inflammatory diseases, including psoriasis2 and hidradenitis suppurativa (HS).3 Tuberculosis (TB) is the most prevalent infectious complication with an increase in the diagnosis among patients receiving anti–TNF-α therapy.4 Therefore, TB screening before biological therapy is extremely important to avoid this complication.
MeSH terms
- Adalimumab
- Medicine
- Hidradenitis suppurativa
- Tuberculosis
- Tumor necrosis factor alpha
- Immune system
- Immunology
- Monoclonal antibody
- Complication
- Monoclonal antibody therapy
- Antibody therapy
- Dermatology
- Antibody
- Immunotherapy